Acute lipidemic effect of calcium heparin in normolipemic and hyperlipemic subjects.

The Authors investigated the lipidometabolic effects of calcium heparin in order to assess if the antiatherogenic usefulness of the drug, recently demonstrated in the treatment of thrombosis and myocardial reinfarction, may be linked to its hypolipemiant property in addition to the antithrombotic one. The series consists of 25 normal-weight subjects (9 m, 16 f, mean age 68 +/- 5, RBW 107 +/- 3) of whom 11 were normolipemics (group A) and 14 hyperlipemics (group B) suffering from hyperlipoproteinemia of type IIA (4 cases), IIB (6 cases) and IV (4 cases). After an overnight fasting each subject was given calcium heparin (12,500 Units in a single dose subcutaneously); before and after 20', 1 hr, 2 hr and 6 hr venous blood samples were taken; for each sample plasma levels of triglyceride, total LDL-, total HDL-, HDL-3-, HDL-2-cholesterol, apoprotein CII, and apoprotein CIII were determined.

[Cholesterol fractions in subjects with cerebral, coronary and peripheral vasculopathy].

An epidemiological investigation of certain lipaemic parameters in some expressions of atherosclerotic disease with particular reference to HDL-cholesterol fractions is reported. The series consists of 94 normal weight subjects (45 m, 49 f, average age 61 +/- 5) subdivided as follows: 38 suffering from cerebral vasculopathy (group A), 41 from ischaemic cardiopathy (group B), 15 from peripheral vasculopathy (group C). One hundred controls aged between 41 and 70 and free from hepato-renal, endocrinometabolic and vascular diseases were also considered.